ly higherin patients with type lIb and IV hyperlipoproteinemias then in controls. In contrast, the established risk factor, total cholesterol/high-density lipoprotein cholesterol ratio, was significantly higher in patients with type ha and IV hyperlipoproteinemias.
Discriminant analysis indicated that prediction of risk for coronary heart disease on the basis of lipoprotein phenotypes can be improved by about 20% when both the above factors are assessed concurrently. On the basis of earlier studies in humans and animals, we also suggest that the proposed risk factor may provide a better understanding of events leading to enhanced risk for coronary heart disease as a consequence of nutrition and of abnormal metabolism of lipids and lipoproteins.
AdditIonal Keyphrases: risk factor -heart disease total cholesterol . lipoprofein phenotypes discriminant analysis
The biological function of serum pseudocholinesterase (PChE; EC 3.1.1.8) has not been clearly established.
A recent review (1) describes several possible physiological roles for it in health and disease. Most importantly, PChE may be involved in lipid (2) and lipoprotein metabolism (3). Its activity is increased in patients with hyperlipoproteinemia, obesity (4, 5) and diabetes (6) .
A positive correlation between high risk for coronary heart disease and increased concentrations of low-density lipoprotein (LDL) has been well documented (7) . In contrast, it has been suggested that an increased concentration of high-density lipoprotein (HDL) may confer a low risk for heart disease. A more recent study (8) , however, suggests that the ratio between LDL cholesterol and HDL cholesterol is a better indicator of risk rather than either of them alone, on the premise that LDL transports the cholesterol produced in the liver to the extra-hepatic tissues and HDL brings it back into the liver for further metabolism.
Currently, many clinical chemistry laboratories, including ours, report the risk factor by calculating the ratio between total cholesterol and HDL cholesterol. We therefore term this ratio the "established risk factor," or ERF. In our previous study (9) we calculated the ratio between serum PChE and HDL cholesterol and termed it the "complementary risk factor" (CRF). This new risk factor correlated well with ERF in individuals classified as low, medium, and high risk. In the same study we also found that CRF might be more closely associated with triglyceride-dependent hyperlipoproteinemias.
We undertook this current investigation to obtain more details of the distribution of CRF in various types of hyperlipoproteinemias.
Materials and Methods
Blood was sampled from each individual after an overnight fast of 14-16 h. Serum was separated from the clot and used for all the analyses. Serum PChE was measured with acetylthiocholine as the substrate (10). The enzyme activity in international (IUB) units (U), defined as the activity of enzyme that converts 1 mol of substrate in 1 mm at 30 #{176}C, is here multiplied by 1000. Serum triglycerides (11) and total cholesterol (12) were measured by enzymatic procedures.
Total LDL was measured by turbidimetry (13), with use of heparmn and calcium chloride. HDL cholesterol was measured in the supernatant fluid after precipitation of the serum with heparmn-manganese chloride (14).
Results
This study included 395 adult patients, classified as types Ha, Hb, and IV hyperlipoproteinemias on the basis of the concentrations of cholesterol (>2500 mg/L), triglycerides (>1850 mg/L), and total LDL in their serum. We also evaluated the intensity of lipoprotemn bands after separation by polyacrylamide gel electrophoresis as recommended by the World Health Organization
(15).
The following were measured for each individual: PChE; HDL cholesterol; triglycerides; total cholesterol; and total LDL (i.e., LDL + VLDL). We then calculated the following ratios: ERF = total cholesterollHDL cholesterol and CRF = PChE/HDL cholesterol. The data, as shown in Table 1 indicates that either CRF or ERF alone can predict the risk for coronary heart disease in 45% of the cases.However, when these factors are combined the predictive value is increased to 65%.
Discussion
Previously we proposed (9) that CRF may be an additional valuable index in predicting the risk for coronary heart disease associated with hypertriglyceridemia and hyper-#{149} pre-beta-lipoproteinemia.
The next question is whether an increase in serum triglycerides with a concomitant increase in VLDL has any role in the development of atherosclerosis. Studies (17) have demonstrated a significant increase in plasma triglyceride and VLDL in many patients with ischemic heart disease, and it has been suggested that the VLDL remnants formed after the action of lipoprotein lipase are capable of inducing atherosclerosis.
Another Statistical analysis of our data indicates that only 45% of the risk for coronary heart disease can be predicted on the basis of lipoprotein proffle if ERF or CRF alone is used. However, when both factors are combined the prediction can be improved by about 20%. Among the hyperlipoproteinemic patients we examined, about 40% are classified as type N hyperlipoproteinemia (Table 1) . Serum cholesterol may not be significantly increased in these patients; as a result, ERF will be a poor predictor of risk. In contrast, CRF appears to be a good predictor of risk in patients with abovenormal VLDL and triglycerides.
In type Ha hyperlipoproteinemia, on the other hand, ERF is a better marker than CRF. In the mixed type of hyperlipoproteinemia (Type JIb), both factors are equally good. Under these circumstances, we believe that using ERF and CRF concurrently will cover a wider spectrum of the population who are at risk because of their abnormal lipid and lipoprotein metabolism.
